<DOC>
	<DOCNO>NCT00876824</DOCNO>
	<brief_summary>The purpose study determine whether single bolus dose Amphoterin B lipid emulsion ( Amphomul ) efficacious safe compare single dose Liposomal Amphotericin B treat patient Indian Visceral Leishmaniasis ( Kala Azar ) .</brief_summary>
	<brief_title>To Study Effect Of Single Infusions Of Amphotericin B Lipid Preparations Treatment Patients Of Kala Azar</brief_title>
	<detailed_description>Visceral Leishmaniasis , progressive fatal treat , insidious , chronic disease characterize irregular fever , anorexia , weight loss , cough , gross enlargement spleen liver , mild anemia emaciation . This may precede rigor vomit . If untreated , Kala-azar , severe form Leishmaniasis , mortality rate nearly 100 % . The goal project establish single dose AMPHOMUL® use achieve Definitive cure Visceral Leishmaniasis lead short course therapy . The project also seek establish AMPHOMUL ® safe , least effective affordable current treatment , without risk drug resistance . The trial Prospective , Multicentric , Randomized , Two Arm , Open label Phase III study Assess Efficacy Safety Infusion Amphomul® ( Amphotericin B Emulsion ) Compared Liposomal Amphotericin B Patients Visceral Leishmaniasis ( Kala azar ) either treatment naive treatment resistant antileishmanial drug .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Male female patient age 5 65 year ( inclusive ) . Clinical sign symptom Visceral Leishmaniasis ( fever 2 week duration splenomegaly ) Presence amastigotes ( LeishmaniaDonovani body ) prescreening detect rK39 dipstick test confirmation splenic bone marrow aspirate smear examination . Nonpregnant , nonlactating female age ≥5 year , woman childbearing potential willing use acceptable method contraception Negative Urine pregnancy test ( UPT ) woman Patients past history treatment Amphotericin B drug Visceral Leishmaniasis within 30 day prior screen . Patients positive HIV , HCV HBsAg infection , immunocompromised patient ( history ) . Concurrent diabetes , tuberculosis bacterial pneumonia infectious major psychiatric disease . Pregnant nursing woman Patients receive medication prohibit study protocol . Simultaneous participation another trial receive IP &lt; 30 day prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Black Fever</keyword>
	<keyword>Kala-Azar</keyword>
	<keyword>Amphotericin B lipid emulsion</keyword>
	<keyword>Liposomal Amphotericin B</keyword>
</DOC>